Cencora to Host Inaugural Product Showcase
Cencora, a global healthcare company, will host its inaugural Product Showcase, an event that will provide increased visibility into the company’s portfolio of solutions and the products it’s developing to support the evolving needs of its customers.
During the virtual event, scheduled for December 3 at 11:00am ET, Cencora executives and leaders from across the organization will highlight innovative partnerships and provide updates on new product offerings. The solutions in development span the continuum of healthcare — from clinical trial enablement to optimizing medication inventory and building a more resilient supply chain.
“Our approach to innovation involves customers at each step of the process,” said Jason Dinger, Senior Vice President, Strategy Execution. “Given our position at the center of the pharmaceutical supply chain, we have a deep appreciation for the challenges our provider customers and manufacturing partners face today, and we are committed to bringing the full breadth of our talents and resources to help them solve today and tomorrow’s challenges. The Product Showcase reflects our commitment to continually evolve while introducing solutions and establishing partnerships that help advance access to healthcare globally.”
During the event, leaders will discuss:
- Cencora’s portfolio of services and solutions for healthcare providers, including solutions designed to help customers proactively plan and manage their medication inventory
- Clinical trial enablement solutions designed to reduce the time and cost involved in bringing therapies to market, with a specific focus on patient recruitment and sourcing for comparator drugs and medical equipment
- Solutions aimed at building a more resilient pharmaceutical supply chain
- Cencora’s Innovation Partnership Program and how the company is collaborating with customers to help build tomorrow’s health care solutions
For more information or to register for the event, please visit: https://web.cvent.com/event/6a21d2a1-cdf3-4b37-a94a-7fdeb06063d2/summary
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241126521224/en/
Contacts
Media
Michelle Engro
215-272-3374
michelle.engro@cencora.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Volvo Cars and HCLTech Collaborate to Drive Engineering Transformation12.6.2025 15:08:00 EEST | Press release
HCLTech, a leading global technology company, today announced that Volvo Cars has chosen HCLTech as one of its strategic suppliers for engineering services. Volvo Cars has been at the forefront of automotive innovation for many years and has set out to shape the future of mobility with strong ambitions on sustainable growth, as it seeks to offer clients the freedom to move in a personal, sustainable and safe way. Drawing on an established relationship in digital and PLM services, this agreement significantly expands HCLTech’s role to cover the delivery of end-to-end engineering solutions at scale. The strategic collaboration will see the company support Volvo Cars’ engineering future ambitions from its automotive Centre of Excellence in Gothenburg, as well as its global offshore and nearshore delivery centers. “We are proud to broaden our relationship with Volvo Cars at such a pivotal moment in its transformation journey,” said Pankaj Tagra, HCLTech Corporate Vice President, Manufactur
KAYTUS Unveils Upgraded MotusAI to Accelerate LLM Deployment12.6.2025 14:11:00 EEST | Press release
KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, today announced the release of the latest version of its MotusAI AI DevOps Platform at ISC High Performance 2025. The upgraded MotusAI platform delivers significant enhancements in large model inference performance and offers broad compatibility with multiple open-source tools covering the full lifecycle of large models. Engineered for unified and dynamic resource scheduling, it dramatically improves resource utilization and operational efficiency in large-scale AI model development and deployment. This latest release of MotusAI is set to further accelerate AI adoption and fuel business innovation across key sectors such as education, finance, energy, automotive, and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612546292/en/ MotusAI Dashboard As large AI models become increasingly embedded in real-world applications, enterprises are
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 14:00:00 EEST | Press release
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefi
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 14:00:00 EEST | Press release
As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s coming next,” said Andrew Busch, economic futurist and economist at AndrewBusch.com. “Tariffs are no longer just a policy lever; they’re a strategic force reshaping the g
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce the company’s strategic vision to redefine the standard of care for B-cell malignancies. “The data presented at EHA 2025 underscore the strength of BeOne’s comprehensive hematology pipeline, built on the success of BRUKINSA, the only BTK inhibitor to demonstrate superior progression-free survival over ibrutinib in a Phase 3 trial,1” said Lai Wang, Ph.D. Global Head of R&D at BeOne. “With our potentially best-in-class BCL2 inhibitor, sonrotoclax, and fi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom